Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 532

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B

Rai, KR, Holland, JF, Glidewell, OJ, Weinberg, V, Brunner, K, Obrecht, JP, Preisler, HD, Nawabi, IW, Prager, D, Carey, RW, Cooper, MR, Haurani, F, Hutchison, JL, Silver, RT, Falkson, G, Wiernik, P, Hoagland, HC, Bloomfield, CD, James, GW, Gottlieb, A, Ramanan, SV, Blom, J, Nissen, NI, Bank, A, Ellison, RR, Kung, F, Henry, P, McIntyre, OR, Kaan, SK·1981·Blood

Abstract

In a randomized study of acute myelocytic leukemia (AML), 352 patients of all ages were treated for remission induction by one of the four regimens: 7 days of cytosine arabinoside (ara-C) by continuous intravenous (i.v.) infusion or bolus injection every 12 hr, together with daunorubicin (DNR) by rapid i.v. injection on days 1, 2, 3; or 5 days of ara-C by infusion or bolus injection and DNR for 2 days only. The regimen of 7 and 3 infusion was significantly superior to the other 3 regimens, resulting in 56% complete remission (CR). For remission maintenance, ara-C was given for 5 days every month and each month one of the following four drugs added on a cyclic rotational basis: thioguanine, cyclophosphamide, CCNU, or DNR. Although ara-C dosage each month was the same, the route of ara-C administration by random allocation was either rapid i.v. bolus or subcutaneous (s.c.) injection. The median duration of CR was significantly longer for s.c. ara-C group: 14 mo for patients less than 60 yr old (versus 8 mo for i.v.) and 31 mo for 60 or older age group (versus 9 mo for i.v.). Patients who received a combination of the best of the four induction regimens (7 and 3 infusion) and the better of the two maintenance schedules (s.c. ara-C) had a median remission duration of 22 mo and a median survival of 35 mo (the longest reported in a prospective randomized trial of therapy for AML). These results establish the validity of an intensive chemotherapy to produce rapid marrow aplasia followed by a sequential maintenance therapy for achieving prolonged disease-free survival in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v58.6.1203.1203

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 532

Metadata

Authors
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., Cooper, M., Haurani, F., Hutchison, J., Silver, R., Falkson, G., Wiernik, P., Hoagland, H., Bloomfield, C., James, G., Gottlieb, A., Ramanan, S., Blom, J., Nissen, N., Bank, A., Ellison, R., Kung, F., Henry, P., McIntyre, O., & Kaan, S.
Venue
Blood
Published
1981-12-01
Volume
58
Issue
6
Pages
1203-1212
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W207118996
Cited by
532
References
12
FWCI
16.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. https://app.cochat.ai/papers/10.1182/blood.v58.6.1203.1203
The paper
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., Cooper, M., Haurani, F., Hutchison, J., Silver, R., Falkson, G., Wiernik, P., Hoagland, H., Bloomfield, C., James, G., . . . Kaan, S. (1981). Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. https://doi.org/10.1182/blood.v58.6.1203.1203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.